Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

423
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
423
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

557
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
557
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

324
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
324

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hamostaseologie·2026
Same author

The Impact of Human ABO Blood Groups on Thrombin Generation in Platelet-Poor Plasma.

Clinical laboratory·2026
Same author

Soluble versus Platelet-Bound P-Selectin as Biomarkers for Preeclampsia: a Dual Meta-Analysis of Diagnostic and Predictive Accuracy.

Clinical laboratory·2026
Same author

Hamostaseologie·2026
Same author

[Digitalisierung im Gesundheitswesen - eine kritische Bestandsaufnahme].

Hamostaseologie·2026
Same author

Neue Probleme der Digitalisierung (eHBA), Gentherapie der Hämophilie, BDDH-Veranstaltung auf Jahrestagung der GTH 2026 in Bonn.

Hamostaseologie·2026

Related Experiment Video

Updated: Feb 28, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K

[Oral anticoagulation using coumarins - an update].

Christoph Sucker1, Jens Litmathe2

  • 1Gerinnungszentrum Berlin Dr. Sucker, Tauentzienstraße 7b/c, 10789, Berlin, Deutschland. sucker@gerinnungszentrum-berlin.de.

Wiener Medizinische Wochenschrift (1946)
|June 14, 2017
PubMed
Summary

Vitamin K antagonists (VKAs) are crucial for preventing and treating blood clots in conditions like atrial fibrillation and after heart valve replacement. This overview covers their mechanism, uses, and management for neurologists.

Keywords:
AlternativesCoumarinsIndicationsReviewSelf-management

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.4K
Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

9.0K

Related Experiment Videos

Last Updated: Feb 28, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.4K
Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

9.0K

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Vitamin K antagonists (VKAs) are essential for managing thrombotic and thromboembolic disorders.
  • Key indications include venous thrombosis, pulmonary embolism, atrial fibrillation, and mechanical heart valve replacement.
  • These anticoagulants are highly relevant in cardio-neurological practice.

Purpose of the Study:

  • To provide a comprehensive overview of Vitamin K antagonists (VKAs).
  • To focus on the mode of action, indications, and efficacy of VKAs.
  • To discuss practical treatment aspects, side effects, and monitoring of VKAs.

Main Methods:

  • Literature review and synthesis of current evidence on VKAs.
  • Analysis of clinical guidelines and practice recommendations.
  • Focus on practical application in neurological and cardiological settings.

Main Results:

  • VKAs effectively prevent and treat thromboembolic events across various indications.
  • Understanding VKA's mechanism is key to optimizing therapeutic outcomes.
  • Careful monitoring and management of side effects are crucial for patient safety.

Conclusions:

  • Vitamin K antagonists remain vital in managing thromboembolic conditions, particularly in patients with atrial fibrillation and mechanical heart valves.
  • Neurologists require a thorough understanding of VKA therapy for effective cardio-neurological patient care.
  • Optimal VKA treatment involves balancing efficacy with vigilant monitoring and side effect management.